Onconeural antibodies are essential to diagnose paraneoplastic neurological syndromes (Q36459516)

14 August 2017

1 reference

title

Onconeural antibodies are essential to diagnose paraneoplastic neurological syndromes (English)

1 reference

14 August 2017

J Honnorat

1 reference

14 August 2017

publication date

1 January 2006

1 reference

Acta neurologica Scandinavica. Supplementum

14 August 2017

published in

1 reference

14 August 2017

volume

183

1 reference

14 August 2017

page(s)

64-68

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00620.X

14 August 2017

1 reference

Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00620.X

Immunomodulatory treatment trial for paraneoplastic neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00620.X

Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00620.X

Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00620.X

Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00620.X

Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00620.X

Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00620.X

Clinical analysis of anti-Ma2-associated encephalitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00620.X

Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00620.X

P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00620.X

Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00620.X

Peptides derived from the onconeural HuD protein can elicit cytotoxic responses in HHD mouse and human

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00620.X

FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00620.X

The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00620.X

Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00620.X

Magnetization transfer and diffusion tensor MRI show gray matter damage in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00620.X

10.1111/J.1600-0404.2006.00620.X

21 January 2018

Identifiers

DOI

0 references

1 reference